Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease
The DOI matches its Crossref record.
Abstract
OBJECTIVES: Levodopa is the immediate precursor of dopamine and the substrate for DOPA decarboxylase, an enzyme subject to regulation in living brain. To test whether this regulation changes in disease, we used Positron Emission Tomography (PET) with parametric mapping to measure the effect of levodopa on the net clearance of [(18)F]fluorodopa to brain (K, ml/g/min). METHODS: Five patients with early Parkinson's disease with pause of medication for 3 days and six age-matched healthy volunteers were studied in a baseline condition and after levodopa challenge. RESULTS: Levodopa (200 mg as Sinemet) increased the magnitude of the net clearance K in the left and right putamen of the healthy volunteers by 11% relative to the baseline condition. In contrast, resumption of medication with levodopa did not significantly alter the magnitude of K in putamen of the Parkinson's disease patients. Compartmental analysis was used to probe the physiological basis of the activation of K: levodopa treatment increased by 15% the apparent distribution volume of [(18)F]fluorodopa in cerebellum (, ml/g) of both patients and control subjects, without significantly altering the unidirectional blood-brain clearance (, ml/g/min) or the relative activity of DOPA decarboxylase (, min(-1)) in putamen. CONCLUSION: We conclude that levodopa treatment increases the distribution volume of [(18)F]fluorodopa in brain, increasing its availability for utilization in dopamine terminals. We speculate that levodopa act as a direct beta-adrenergic agonist at receptors regulating the permeability of the blood-brain barrier to levodopa. However, the PET analytical method was without sufficient power to detect the consequent increase in magnitude of K in brain of only five Parkinson's disease subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers.
Liggins, J., Pihl, R. O., Benkelfat, C., & Leyton, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028370 · Cited by 58
Siessmeier, T., Kienast, T., Wrase, J., Larsen, J. L., Braus, D. F., Smolka, M. N., Buchholz, H. G., Schreckenberger, M., Rösch, F., Cumming, P., et al. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04903.x · Cited by 48
Self-citationA shift of paradigm: From noradrenergic to dopaminergic modulation of learning?
Breitenstein, C., Flöel, A., Korsukewitz, C., Wailke, S., Bushuven, S., & Knecht, S. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.05.012 · Cited by 44
Metadata
- Authors
- Kumakura, Y., Danielsen, E. H., Reilhac, A., Gjedde, A., & Cumming, P.
- Venue
- Acta Neurologica Scandinavica
- Publisher
- Hindawi Limited
- Published
- 2004-09
- Volume
- 110
- Issue
- 3
- Pages
- 188-195
- ISSN
- 0001-6314 (ISSN-L)
- 1600-0404
- OpenAlex
- W2044260808
- Cited by
- 30
- References
- 0
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease. https://app.cochat.ai/papers/10.1111/j.1600-0404.2004.00299.x
- The paper
- Kumakura, Y., Danielsen, E. H., Reilhac, A., Gjedde, A., & Cumming, P. (2004). Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease. Acta Neurologica Scandinavica. https://doi.org/10.1111/j.1600-0404.2004.00299.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.